WASHINGTON (Reuters) - The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha over a legal challenge by French rival Sanofi SA.
The decision upheld a lower court's ruling that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating the full scope of its claimed innovation.
(Reporting by John Kruzel; Additional reporting by Andrew Chung; Editing by Will Dunham)
By John Kruzel
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 87.7 EUR | -1.29% | +1.76% | 117B | ||
| 273 USD | -0.19% | +3.39% | 146B | ||
